Τίτλος:
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
During the last decades, the knowledge on follicular cell-derived thyroid cancer molecular biology has led to the evolution of a number of novel therapies for these tumors, mainly tyrosine kinase inhibitors. Lenvantinib, sorafenib and recently cabozantinib have been approved for differentiated thyroid cancer (DTC), while larotrectinib and entrectinib for neurotrophic-tropomyosin receptor kinase-fusion thyroid cancer. For radioiodine (RAI) refractory DTCs ongoing research aims to identify agents that may restore RAI-avidity via redifferentiation protocols (vemurafenib or dabrafenib and trametinib) or combination treatments. These treatments are based on the tumor molecular signature. The treatment with targeted therapies has changed the therapeutic strategies and the disease prognosis, however drug resistance remains the main reason for treatment failure. Thus, the understanding of both molecular pathways implicated in tumorigenesis, and tumoral escape mechanisms, are of paramount significance for the development of new therapies for DTC. The present review focuses on the molecular landscape of DTC, the approved targeted therapies as well as the mechanisms of drug resistance. Furthermore, it points to the ongoing research and the future perspectives for the development of more efficient drugs for DTC.
Συγγραφείς:
Karapanou, O.
Simeakis, G.
Vlassopoulou, B.
Alevizaki, M.
Saltiki, K.
Περιοδικό:
Endocrine-Related Cancer
Λέξεις-κλειδιά:
protein kinase inhibitor; radioactive iodine; sorafenib, adenocarcinoma; human; pathology; thyroid tumor, Adenocarcinoma, Follicular; Humans; Iodine Radioisotopes; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms
